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There are contrasting data in the literature about antituberculosis plasma drug concentrations in HIV-1-coinfected patients. We
report the pharmacokinetics of rifampin, isoniazid, and pyrazinamide in a cohort of patients being treated for active tuberculo-
sis, the majority of whom were coinfected with HIV-1 and had commenced antiretroviral therapy within 2 months of starting
antituberculosis treatment. We also examined the association between antituberculosis drug concentrations and reported drug
side effects at the 2-month clinical review. One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were
intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily qua-
druple-therapy regimen dosed according to World Health Organization (WHO) weight bands. Pharmacokinetic parameters
were determined for each patient by using nonlinear mixed-effects models. HIV-1-coinfected patients had lower clearance rates
for rifampin (21% decrease) and isoniazid (23% decrease) than HIV-1-uninfected patients, with resulting higher areas under the
concentration-time curve from 0 to 24 h (AUC0 –24) and maximum concentrations of drug in serum (Cmax). Antiretroviral ther-
apy (ART) that included double-standard-dose lopinavir/ritonavir further lowered rifampin clearance, by 46%, and increased
the AUC0 –24. The current uniform dosing (per kilogram of body weight) across WHO weight bands was associated with a trend
of decreased pharmacokinetic exposures for the lowest weight band. Use of fat-free mass as opposed to total body weight for al-
lometric scaling of clearance significantly improved the model. Ambulant HIV-1-coinfected patients, the majority of whom were
coprescribed ART, did not have reduced antituberculosis drug concentrations compared to HIV-1-uninfected patients.
Despite global initiatives prioritizing reductions of the inci-dence and mortality attributable to tuberculosis (TB), in
2014 there were an estimated 9.6 million new TB cases (12% of
patients were coinfected withHIV-1) and 1.5million deaths (27%
of patients were coinfected with HIV-1) (1). In the case of rifam-
pin-susceptible pulmonary tuberculosis,World Health Organiza-
tion (WHO) guidelines advocate a daily regimen of 2 months of
intensive-phase therapy with the first-line drugs rifampin, isoni-
azid, pyrazinamide, and ethambutol followed by 4months of con-
tinuation-phase therapy with rifampin and isoniazid. Fixed-dose
combination formulation (FDC) tablets are widely used to deliver
standardized doses according to weight (2).
There aremultiple causes leading to significant interindividual
pharmacokinetic (PK) variability, including pharmacogenomics
(3, 4), sex (5, 6), weight (6), and comorbidities, such as diabetes
mellitus (5, 7–9). There have been contrasting findings published
regarding the effect of HIV-1 coinfection on anti-TB drug phar-
macokinetics, with some studies showing reduced drug exposures
(10–12) and others showing no significant difference between
HIV-1-coinfected and -uninfected patients (5, 13–15). Of note,
the cohorts studied had various degrees of nutritional deprivation
and immunosuppression and various proportions of patients
concurrently taking antiretroviral therapy (ART). As other studies
have shown contradictory findings on the role of plasma drug
concentrations of anti-TB drugs, we thus wished to further ad-
dress this in a contemporary cohort with good access to ART,
resulting in many patients on ART and in HIV-1-coinfected pa-
tients generally being less advanced in terms of immunosuppres-
sion than the case in historical reports.
We hypothesized that there would be lower plasma drug concen-
trations of anti-TB drugs in HIV-1-coinfected patients than in HIV-
1-uninfected patients.We aimed to assess pharmacokinetic parame-
ters of rifampin, isoniazid, and pyrazinamide in a cohort with an
adequate sample size by utilizing strong pharmacokinetic analysis
methods toallowrelativelyaccuratedelineationandattributionofPK
variability. Due to budgetary constraints, we focused on the three
drugs with foremost importance in the anti-TB regimen (16).
The relationship between drug concentrations of standard-dose
first-lineanti-TBdrugsanddrugsideeffectprofiles isunclear. Serious
adverse drug reactions (common terminology criteria for adverse
events [CTCAE] [17] grade 3 and above), such as drug-induced hep-
atotoxicity, are well documented and can sometimes be attributed to
a specific anti-TB drug based upon temporality, cessation, and se-
quential drug rechallenge (18). Mild tomoderate drug side effects of
CTCAE grades 1 and 2 are common (19–21). Although thesemay be
difficult to attribute to a specific anti-TBdrugwith any certainty, they
are likely to contribute to suboptimal adherence (22) and may ad-
versely affect treatment outcomes (19).
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We also aimed to determine whether plasma drug concentra-
tions were associated with reported drug side effects at 2 months.
MATERIALS AND METHODS
Patients. Patients with GeneXpert MTB/RIF-confirmed rifampin-sus-
ceptible pulmonary TB were recruited at the Ubuntu HIV/TB Clinic, Site
B, Khayelitsha, South Africa, as part of a prospective cohort study (Hu-
man Research Ethics Committee approval 568/2012) assessing the fre-
quency and determinants of acquired drug resistance in a programmatic
setting. A subcohort was invited to participate in a nested pharmacoki-
netic study between July 2013 and April 2014. All patients provided writ-
ten consent prior to participation. Detailed sociodemographic data, past
TB treatment history, and comorbidity data were collected. Participants
underwentHIV testing (Abbott ArchitectHIVAg/AbCombo test), a CD4
lymphocyte count, and HIV-1 viral load quantification at baseline. An-
ti-TB drugs were delivered in a 4-drug FDC supplied by the National
Tuberculosis Control Programme (Rifafour e-275 [Sanofi-Aventis] or
Ritib [Aspen, South Africa]). Each tablet contained rifampin at 150 mg,
isoniazid at 75 mg, pyrazinamide at 400 mg, and ethambutol at 275 mg.
Weight band-based dosing was used in line with WHO guidelines (2).
Patients weighing 38 to 55 kg,55 to 70 kg, and70 kg were given doses
of 3, 4, and 5 tablets, respectively. Anti-TB drugs were administered 7
days/week, along with 25 mg pyridoxine. Clinical care remained the re-
sponsibility of the Site B TB clinic.
Characterization of side effects. Patients were interviewed at the
2-month clinical reviewby use of a systems-based symptomquestionnaire
TABLE 1 Clinical characteristics of the cohort, stratified by HIV-1 serostatus
Clinical characteristica
Value
Whole PK cohort
(n 100)
HIV-1-infected patients
(n 65)
HIV-1-uninfected patients
(n 35)
Male (no. [%]) 57 (57) 30 (46) 27 (77)
Xhosa ethnicity (no. [%]) 98 (98) 63 (97) 35 (100)
Median (IQR) age (yr) 33 (29–40) 34 (30–40) 32 (27–38)
No. (%) of patients with smoking history
Current 24 (24) 9 (14) 15 (43)
Previous 27 (27) 19 (29) 8 (23)
Never 49 (49) 37 (57) 12 (34)
No. (%) of patients with characteristic
Alcohol consumption 37 (37) 16 (25) 17 (49)
Recreational drug use 5 (5) 3 (5) 2 (6)
Previously in prison 14 (14) 10 (15) 4 (11)
Previous mining history 5 (5) 1 (1) 4 (11)
Retreatment 39 (39) 29 (45) 10 (29)
Type 2 diabetes mellitus 4 (4) 3 (5) 1 (3)
Median (IQR) BMI at baseline (kg/m2) 21 (19–23) 21 (20–23) 20 (19–23)
Median (IQR) BMI at PK study (kg/m2) 21.5 (20–23) 22 (20–23) 20.5 (19–23)
Median (IQR) FFM at PK study (kg) 45 (38–49) 40.5 (36–47) 49 (46–51)
Median (IQR) CD4 count (cells/mm3) 233 (106–386)
No. (%) with viral load of40 copies/ml at baseline 17 (26)
Median (IQR) albumin concn at PK study (g/liter) 38 (34–40) 36 (34–39) 38 (40–43)
Median (IQR) total protein concn at PK study (g/liter) 86 (79–92) 88 (82–93) 82 (75–86)
Median (IQR) time on ART at time of PK study (mo) 1.32 (0–15.5)
No. (%) of patients with smear grade at baseline
3 24 (24) 14 (21.5) 10 (29)
2 22 (22) 11 (17) 11 (31)
1 20 (20) 14 (21.5) 6 (17)
Scanty/negative 34 (34) 26 (40) 8 (23)
Median (IQR) baseline time to culture positivity (days) 10 (7–14) 12 (7–15) 8 (6.5–12.5)
No. (%) of patients with extensive radiological disease at baseline 71 (71) 41 (63) 30 (86)
No. (%) of patients with cavities at baseline 52 (52) 32 (49) 20 (57)
Median (range) dose at PK study (mg/kg)
Rifampin 10 (7–11.5) 10 (7–11.5) 10 (7–11.5)
Isoniazid 5 (3.5–6) 5 (4–6) 5 (3.5–6)
Pyrazinamide 26 (19–31) 26 (20–31) 25.5 (19–31)
No. (%) of patients with side effects of TB treatment 35 (35) 25 (38) 10 (29)
No. (%) of poorly adherent patients per pill counts/self-reports
at 2-month review
10 (10) 8 (12) 2 (6)
a Characteristics are reported for the time of diagnosis (baseline) unless otherwise specified (at PK visit or 2-month visit). Abbreviations: BMI, body mass index; FFM, fat-free mass;
ART, antiretroviral therapy; PK, pharmacokinetics.
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that included the categories central nervous/neuropsychiatric, peripheral
nervous, gastrointestinal, musculoskeletal, skin, and other. Attribution of
causality to the anti-TB regimen was made in the “probable”/“possible”
categories per the WHO-Uppsala Monitoring Center system (18).
Pharmacokinetics. Pharmacokinetic sampling was carried out for ri-
fampin, isoniazid, and pyrazinamide after 7 to 8 weeks of anti-TB drugs.
This time point was chosen to maximize applicability to a programmatic
setting, i.e., a point of routine evaluation prior to switching from inten-
sive-phase to continuation-phase therapy. In addition, this time point
ensured that a majority of HIV-1-coinfected patients were prescribed
ART and that rifampin autoinduction would be complete. Patients fasted
for 8 h on the day of pharmacokinetic study and consumed standardized
meals at 2 h and 4 to 5 h postdose. Blood samples were obtained imme-
diately before (predose) and 1, 2, 3, 4, 6, and 8 h after drug ingestion. They
were immediately placed on ice, and plasma was separated by centrifuga-
tion within 30 min before storage at 80°C until analysis. The storage
tubes containing the plasma samples were transferred on dry ice to the
Pharmacology Laboratory at the University of Cape Town, where drug
concentrations were determined using validated liquid chromatography-
tandem mass spectrometry (LC-MS/MS) methods. The methods were
validated over the following concentration ranges: 0.0977 to 26.0 g/ml
for isoniazid, 0.117 to 30.0 g/ml for rifampin, and 0.200 to 80.0 g/ml
for pyrazinamide (23). The % nominal concentration (accuracy) values
were 99.2%, 98.1%, and 99.4% for rifampin, 100.5%, 100.1%, and 99.4%
for isoniazid, and 100.8%, 103.7%, and 102.1% for pyrazinamide at the
low, medium, and high quality control levels, respectively, during inter-
day sample analysis. The precision (% coefficient of variation [% CV])
was less than 3% at the low, medium, and high quality control levels.
Concentrations of rifampin, isoniazid, and pyrazinamide below the vali-
dation range of the assay were reported as “below the limit of quantifica-
tion” (BLQ).
Plasma concentration-time data fromall subjects were simultaneously
analyzed by a nonlinear mixed-effects model by utilizing Monolix (ver-
sion 4.3.3; Lixoft). Previously published structural models were selected
and optimizedwith the current data (24–26). The structuralmodels tested
included one- and two-compartment dispositions with first-order elimi-
nation and first-order absorption, with the presence of an absorption lag
time or a delay modeled via a chain of transit compartments. Interocca-
TABLE 2 Parameter values estimated by the final pharmacokinetic model for rifampina
Parameter Estimated typical value (95% CI)
% variability (95% CI), shrinkageb
Interoccasional Interindividual
Bioavailability (F) 1 (fixed) 29.1 (24.2–34.0), 20
Absorption lag time (h) 0.691 (0.590–0.791) 76.2 (62.0–89.9), 24
Absorption constant (h1) 1.21 (1.03–1.38) 63.2 (49.0–77.5), 26
CL/F (liters/h)c
HIV-1-uninfected patients 25.1 (21.8–28.4) 34.3 (28.8–39.8), 10
HIV-1-infected patients not on LPV/r 19.9 (17.8–21.8) 34.3 (28.8–39.8), 10
HIV-1-infected patients on LPV/r 10.8 (7.08–14.5) 34.3 (28.8–39.8), 10
Vol of distribution (liters)c 56.4 (53.7–59.1)
Additive error (mg/liter) 0.196 (0.174–0.218)
Proportional error (%) 15.0 (13.2–16.8)
a Abbreviations: F, bioavailability; LPV/r, lopinavir/ritonavir; 95% CI, 95% confidence interval.
b Interindividual and -occasional variabilities were assumed to be lognormally distributed and are reported here as approximate % CV. For interoccasional variability terms, the
shrinkage is reported only for the occasion with intensive sampling (not the predose).
c Clearance and volume of distribution were allometrically scaled using individual values for fat-free mass (FFM), so the typical values reported here refer to the median value for
FFM in the cohort, i.e., 45 kg (e.g., a 1.7-m tall man weighing 51 kg).
TABLE 3 Parameter values estimated by the final pharmacokinetic model for isoniazid
Parameter Estimated mean population value (95% CI)
% variability (95% CI), shrinkagea
Interoccasional Interindividual
Bioavailability (F) 1 (fixed) 32.3 (27.2–37.4), 12
Mean transit time (h) 0.32 (0.12–0.51) 92.7 (65.3–120), 35
No. of absorption transit compartments 2.04 (1.55–2.53)
Absorption constant (h1) 1.20 (1.03–1.36) 17.7 (11.8–23.6), 60
CL/F (liters/h)b
HIV-1-uninfected patients 26.0 (21.1–30.9) 54.8 (46.9–62.6), 3
HIV-1-infected patients 20.02 (12.9–25.2) 54.8 (46.9–62.6), 3
Vol of distribution of central compartment (liters)b 31.9 (30.8–36.2)
Intercompartmental CL/F (liters/h)b 12.6 (6.13–19.07)
Vol of distribution of peripheral compartment (liters)b 21.4 (18.5–24.4)
Additive error (mg/liter) 0.0146 (0.003–0.03)
Proportional error (%) 13.1 (11.9–14.3)
a Interindividual and -occasional variabilities were assumed to be lognormally distributed and are reported here as approximate % CV. For interoccasional variability terms, the
shrinkage is reported only for the occasion with intensive sampling (not the predose).
b All clearance and volume parameters were allometrically scaled using individual values for fat-free mass (FFM), so the typical values reported here refer to the median value for
FFM in the cohort, i.e., 45 kg (e.g., a 1.7-m tall man weighing 51 kg).
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sional variability (IOV) was included by treating the drug concentration
measured prior to the observed dose administration (predose concentra-
tion) as a separate pharmacokinetic occasion. Random interindividual
variability (IIV) and IOV values were assumed to be lognormally distrib-
uted, and correlations between the random effects were tested. A mixture
model was evaluated to explore the multimodal distribution of isoniazid
clearance (CL) due to the polymorphic N-acetyltransferase-2 (NAT2)
gene. Data points which were BLQ were treated as censored and han-
dled with the Monolix implementation of the M3 method (27). Allo-
metric scaling with either total body weight or fat-free mass (FFM)
(28) was applied to CL and the volume of distribution (V) as suggested
by Anderson and Holford (29). Fat-free mass was calculated using the
empirical model developed by Janmahasatian et al. (30), as follows:
FFM  (WHSmax  ht
2  wt)/(ht2  WHS50  wt), where “wt” de-
notes body weight in kilograms, “ht” denotes height in meters, and the
constants WHSmax and WHS50 have values of 42.92 and 30.93, respec-
tively, for men and 37.99 and 35.98, respectively, for women.
Other covariates tested included the effects of sex, age, serumalbumin,
total protein, HIV serostatus, CD4 lymphocyte count (as a binary vari-
able, i.e., above or below 200 cells/mm3), type of ART (none versus non-
nucleoside reverse transcriptase inhibitor [NNRTI]-based ART versus
protease inhibitor [PI]-based ART), total dose, and dose (doses in milli-
grams per kilogram of body weight). Model development and selection
were based onoptimization of the objective function value (OFV), inspec-
tion of goodness-of-fit plots, including visual predictive checks (n 500),
and biological plausibility. Stepwise covariate selection was performed
using a drop in OFV of 3.84 (corresponding to a significance level of
5%) as the cutoff for inclusion and an increase of6.63 OFV points as a
cutoff for the backward elimination step. The OFV was obtained using
importance sampling (n  20,000), and the precision of the parameter
estimates was obtained using a stochastic approximation based on the
Fisher information matrix.
Finally, model-based individual pharmacokinetic parameter values
referring to the pharmacokinetic profile after the observed dose were used
in the R package Simulx (31) to simulate steady-state individual profiles
and to calculate the peak concentration (Cmax) and the area under the
concentration-time curve from 0 to 24 h (AUC0–24).
Statistical analyses. The Wilcoxon-Mann-Whitney test was used to
compare PK exposures as those with side effects and those without. Lo-
gistic regression analyses were used to calculate odds ratios (ORs) for side
effects at different drug exposure quartiles, and the ORs were adjusted for
potential confounders. Stata, version 13.1 (College Station, TX), and
GraphPad Prism 6.0 (La Jolla, CA) were used for all analyses.
RESULTS
Patient demographics. Of the 100 study participants, 57% were
male and 65% were coinfected with HIV-1, with a median CD4
lymphocyte count of 233 cells/mm3 (interquartile range [IQR],
106 to 386 cells/mm3). Among HIV-1-coinfected patients, the
proportion on ART increased from 27/65 (42%) patients at base-
line to 50/65 (77%) patients at the time of pharmacokinetic study,
with 45/50 (90%) patients on NNRTI-based (96% on efavirenz
and 5% on nevirapine) regimens and 5/50 (10%) patients on PI-
based (lopinavir/ritonavir [LPV/r]) regimens.
The median (IQR) body mass index (BMI) and age were 21
kg/m2 (19 to 23 kg/m2) and 33 years (29 to 40 years), respectively.
Table 1 provides the clinical characteristics of the pharmacoki-
netic cohort, stratified by HIV-1 serostatus.
Patient pharmacokinetic parameters. The final population
pharmacokinetic parameter estimates for rifampin, isoniazid, and
pyrazinamide are shown in Tables 2 to 4, including the precision
of parameter estimates and shrinkage values for the random ef-
fects (32). Visual predictive checks are provided in Fig. 1.
The optimized structural model for rifampin was a one-com-
partment model with first-order elimination and first-order ab-
sorption, with an absorption lag time. A two-compartmentmodel
with first-order elimination and absorption through a series of
transit compartments was optimal for isoniazid. Finally, a one-
compartmentmodelwith first-order elimination and transit com-
partment absorption was used for pyrazinamide. FFM was found
to be the most suitable body size descriptor for allometric scaling
of all CL and V parameters, and it improved the OFV by 20, 34,
and 64 points for rifampin, isoniazid, and pyrazinamide, respec-
tively.
Since HIV-1 serostatus (infected versus not infected) and
ART status (on ART versus not on ART) are colinear, the ef-
fects of the covariates HIV-1 status and ART status on the
pharmacokinetic parameters were tested separately. HIV-1 sta-
tus as a covariate caused improvement in the model to a greater
extent than ART status did (7-point versus 4-point drop in
OFV), and diagnostic plots were better for the model including
HIV-1 status; hence, this was selected in the final model rather
than ART status. The models found that HIV-1 coinfection
significantly decreased the CL of rifampin (21% decrease; OFV
drop of 7.00 points; P  0.01) (Table 2) and isoniazid (23%
decrease; OFV drop of 8.63 points; P  0.01) (Table 3). Inclu-
sion of HIV-1 coinfection in the covariate model did not sig-
nificantly improve the model fit for pyrazinamide. Although
HIV-1-infected participants had lower FFM than HIV-1-unin-
TABLE 4 Parameter values estimated by the final pharmacokinetic model for pyrazinamide
Parameter Estimated population value (95% CI)
% variability (95% CI), shrinkagea
Interoccasional Interindividual
Bioavailability (F) 1 (fixed) 13.1 (10.2–16), 31
Mean transit time (h) 0.74 (0.65–0.84) 54.5 (45.1–63.9), 19
No. of absorption transit compartments 2.06 (1.59–2.53)
Absorption rate constant (h1) 50.0 (fixed)c
Vol of distribution (liters)b 41.9 (40.4–43.4)
CL/F (liters/h)b 4.17 (3.90–4.44) 29.6 (24.7–34.5), 8
Additive error (mg/liter) 1.95 (1.77–2.13)
Proportional error (%) 10.7 (9.60–11.80)
a Interindividual and -occasional variabilities were assumed to be lognormally distributed and are reported here as approximate % CV. For interoccasional variability terms, the
shrinkage is reported only for the occasion with intensive sampling (not the predose).
b All clearance and volume parameters were allometrically scaled using individual values for fat-free mass (FFM), so the typical values reported here refer to the median value for
FFM in the cohort, i.e., 45 kg (e.g., a 1.7-m tall man weighing 51 kg).
c The model estimated a very large value for the absorption constant, so it was fixed to 50 to stabilize the model without significantly affecting the fit.
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fected participants (Table 1), the effect of HIV-1 on CL was
independent of differences in FFM.
We split the covariate ART status into types of ART (i.e., no
ART,NNRTI-basedART, and LPV/r-basedART) and tested these
as further covariates (in addition to theHIV effect).We separately
tested the effects of both NNRTI-based regimens (yes/no) and
LPV/r-based regimens (yes/no) as covariates on bioavailability,V,
and CL in an optimized model which was already adjusted for the
effect of HIV-1 status on CL. On top of the effect of HIV-1 on CL,
patients on a double-dose LPV/r-based ART regimen (dosed at
800 mg/200 mg twice daily in all 5 cases) had a further significant
decrease in rifampin CL of 46% (OFV drop of 7.00 points; P 
0.01), and hence they had an increased AUC0–24 (Table 2). When
the model was rerun with exclusion of the 5 participants on PI-
based regimens, the effect of HIV-1 on CL was still significant.
During model development, the multimodal distribution of
isoniazid CL attributed to the polymorphic nature of the NAT2
genotype (3) was described using a mixture model which im-
proved the model fit. However, the current version of Monolix
does not support both mixture modeling and estimation of in-
teroccasional variability, which was used to describe variability in
the predose sample, so the latter was included because it wasmore
significant in terms of model fit.
Figure 2 shows Cmax and AUC0–24 values stratified by HIV-1
serostatus. For all 3 drugs, either pharmacokinetic exposures were
increased in those infected with HIV-1 or no difference was de-
tected. There were no differences in exposures between HIV-1-
infected patients with CD4 lymphocyte counts above and below
200 cells/mm3. Among HIV-1-infected participants, 41% had a
low isoniazid Cmax (3 mg/liter), 75% had a low rifampin Cmax
FIG 1 (A) Visual predictive check for rifampin concentration versus time, stratified by HIV-1 serostatus and coadministration of lopinavir/ritonavir (LPV/r).
The blue dots are observed concentrations, and the red dots are simulation-based values below the limit of quantification (BLQ). Lines are 10th, 50th, and 90th
percentiles for observed data, while the shaded areas represent the 90% confidence intervals for the same percentiles, as predicted by the model. (B) Visual
predictive check for isoniazid concentration versus time, stratified by HIV-1 serostatus. The blue dots are observed concentrations, and the red dots are
simulation-based values below the limit of quantification (BLQ). Lines are 10th, 50th, and 90th percentiles for observed data, while the shaded areas represent the
90% confidence intervals for the same percentiles, as predicted by the model. (C) Visual predictive check for pyrazinamide concentration versus time. The blue
dots are observed concentrations, and the red dots are simulation-based values below the limit of quantification (BLQ). Lines are 10th, 50th, and 90th percentiles
for observed data, while the shaded areas represent the 90% confidence intervals for the same percentiles, as predicted by the model.
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(8 mg/liter), and 31% had a low pyrazinamide Cmax (35 mg/
liter) (33). Among HIV-1-uninfected participants, 46% had a low
isoniazid Cmax, 88% had a low rifampin Cmax, and 63% had a low
pyrazinamide Cmax.
The ranges of doses (in milligrams per kilogram of body
weight) for the three drugs are shown in Table 1. Eight partici-
pants required a change in weight band during treatment. Three
had their dose adjusted appropriately, one was put in a weight
band higher than his weight, and four were put in a weight band
lower than their weight. Hence, on the day of pharmacokinetic
sampling, 95 participants were being dosed correctly according to
current weight and height bands. Patients in the lowest weight
band had lower drug exposures, and this was explained by a rela-
tively higher CL in smaller individuals. Figure 3 shows differences
in pharmacokinetic exposures stratified by theWHOweight band
doses assigned by the program. The predictions shown included
allometric scaling with FFM, which accounted for the increased
clearance per kilogram of body weight in smaller individuals and
resulted in a significant improvement of the model.
All side effects were of CTCAE grades 1 and 2 and did not
require drug withdrawal. Thirty-five participants (35%) reported
CTCAE grade 1 and 2 side effects which were possibly/probably
attributed to anti-TB drugs, including central nervous system/
neuropsychiatric (4/35 patients), peripheral neuropathy (7/35 pa-
tients), nausea/gastrointestinal (11/35 patients), musculoskeletal
(11/35 patients), skin (8/35 patients), and other (2/35 patients)
effects. Patients presenting side effects had a significantly higher
median Cmax for isoniazid (4.42 mg/liter [IQR, 2.79 to 5.51 mg/
liter]) than those who did not (2.89 mg/liter [IQR, 2.28 to 3.87
mg/liter]) (P 0.001). After adjustments for age, HIV-1 serosta-
tus, diabetesmellitus status, alcohol intake, and previous isoniazid
treatment, the highest quartile of isoniazid AUC0–24 values was
still associated with increased side effects (OR, 7.11 [95% confi-
dence interval, 1.99 to 25.47]; P 0.003) compared to the lowest
quartile of isoniazid AUC0–24 values (Table 5). There were no
significant differences for rifampin or pyrazinamide (Fig. 4). Al-
though there was a trend of high isoniazid Cmax values for those
with central nervous system, peripheral nervous system, gastroin-
testinal, and musculoskeletal side effects, this was statistically sig-
nificant only for musculoskeletal side effects. A significantly
higher pyrazinamide Cmax was also seen for patients with muscu-
loskeletal side effects (Fig. 4).
DISCUSSION
Peak concentrations and AUC0–24 values for rifampin, isoniazid,
and pyrazinamide were low and highly variable, and the findings
were comparable to those for other cohorts in both similar (south-
ern African) (6, 10, 13, 34, 35) and different (36–38) study popu-
lations. There have been previous studies examining anti-TB
pharmacokinetics in HIV-1-coinfected patients and an HIV-1-
uninfected comparator group. However, none of these studies
included HIV-1-coinfected patients concomitantly taking ART.
Reduced rifampin concentrations have been recorded for HIV-1-
coinfected patients with diarrhea, and this has been associated
with malabsorption and advanced immunosuppression (11, 39,
40). Further studies have also shown evidence of reduced rifampin
FIG 2 Pharmacokinetic measures Cmax and AUC0–24, stratified by HIV serostatus and antiretroviral therapy regimen. The box-and-whisker plots show
model-derived PK measures. Cmax and AUC0–24 are plotted on the left and right y axes, respectively. The boxes show medians and interquartile ranges. The
whiskers represent the 5th to 95th percentiles and illustrate the variability in both HIV-1-infected () and HIV-1-uninfected () patients and different
antiretroviral therapy categories. Patients on inhibitors appeared to have higher rifampin AUC0–24 values than patients in the no-ART and NNRTI-based
categories. The dotted black lines indicate the current recommended thresholds for Cmax of 3 mg/liter, 8 mg/liter, and 30 mg/liter for isoniazid, rifampin, and
pyrazinamide, respectively. No tests for statistical significance were run to generate P values for these post hoc individual estimates, as the reported individual
values are based on the population PKmodels and are hence interdependent. The significance of the respective covariate effects (Tables 2 to 4) was tested within
the model. Abbreviations: ART, antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; Cmax, maximum concen-
tration; AUC, area under the curve from 0 to 24 h.
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concentrations in HIV-1-coinfected patients (10, 12), while oth-
ers showedno significant difference (5, 13, 15, 41). There have also
been contrasting results in the literature regarding the effect of
HIV-1 coinfection on the pyrazinamide concentration (10, 42).
In this cohort of ambulatory patients, with 77% of HIV-1-
coinfected patients on ART, there was no evidence of lower
plasma concentrations of rifampin, isoniazid, or pyrazinamide in
HIV-1-coinfected patients. Conversely, the population pharma-
cokinetic model which accounted for the effect of FFM showed
evidence of reduced rifampin and isoniazid CL in HIV-1-coin-
fected compared to HIV-1-uninfected patients, leading to in-
creased AUC0–24 values.
Although the use of ART or CD4 stratification as a covariate
did not significantly improve themodel, therewas an independent
effect of LPV/r versus no LPV/r on the rifampin AUC0–24, which
againwas explained by a reduction inCL.Althoughonly 5 patients
in the study were on an ART regimen inclusive of LPV/r, the effect
of double-dose LPV/r on rifampin exposures was statistically sig-
nificant. This has not been reported previously. Rifampin is a sub-
strate of p-glycoprotein, organic anion-transporting polypeptide
1B1 (OATP1B1), and OATP1B3, which are involved in its trans-
porter-mediated efflux in the liver, and hence in biliary clearance.
Lopinavir and ritonavir are inhibitors of both p-glycoprotein and
OATP1/3 (43). Hence, this may be a potential mechanism for
decreased clearance of rifampin. Inhibition of gastrointestinal p-
glycoprotein may also increase systemic rifampin concentrations.
There are potential implications for dosing and toxicity profiles,
particularly in future regimens incorporating higher doses (per
kilogram) of rifampin, and these findings should be explored in
further pharmacokinetic studies. These results provide evidence
that at the time of switch to the continuation phase, ambulant
HIV-1-coinfected patients undergoing immune reconstitution on
ART do not have reduced anti-TB drug concentrations compared
to HIV-1-uninfected patients. These findings are not necessarily
generalizable to HIV-1-coinfected patients in an inpatient setting
or to those with advanced immunosuppression (the median CD4
count of this cohort was 233 cells/mm3).
As previously reported (6), weight, and in particular FFM, in-
fluenced CL in a nonlinear fashion, and hence uniform dosing (in
milligram per kilogram of body weight) across the WHO weight
bands was associated with the lowest weight band having a trend
of lower drug concentrations than those with the highest weight
band. Therefore, dosing could be optimized according to FFM,
and in particular, dosing for the lower weight band should be
reviewed.
Having adjusted for potential confounders, we still found a
FIG 3 Pharmacokinetic measures Cmax and AUC0–24, stratified by WHO
weight band. The box-and-whisker plots show model-derived PK measures
stratified by WHO weight band. Cmax and AUC0–24 values are plotted on the
left and right y axes, respectively. The boxes show medians and interquartile
ranges. The whiskers represent the 5th to 95th percentiles. The predictions
include allometric scaling, which is necessary to account for nonlinear differ-
ences byweight/size. This explains differences in PKmeasures despite the same
dosing (milligram per kilogram of body weight) by weight band. The dotted
black lines indicate the current recommended thresholds for Cmax of 3 mg/
liter, 8 mg/liter, and 30 mg/liter for isoniazid, rifampin, and pyrazinamide,
respectively. Abbreviations: Cmax, maximum concentration; AUC, area under
the curve from 0 to 24 h; WB, weight band.
TABLE 5 Risk factors for reported side effects at 2-month review by univariate and multivariate models
Variablea OR (95% CI) for reported side effects Adjusted OR (95% CI) for reported side effects
INH AUC0–24 quartile 1 1 1
INH AUC0–24 quartile 2 1.26 (0.34–4.84) 1.19 (0.29–4.87)
INH AUC0–24 quartile 3 1.88 (0.52–6.84) 2.08 (0.54–8.07)
INH AUC0–24 quartile 4 7.11 (1.99–25.47) 9.12 (2.28–36.55)
10-yr increase in age 1.09 (0.71–1.67) 1.14 (0.68–1.92)
Previous isoniazid treatment 1.54 (0.67–3.55) 1.76 (0.63–4.97)
HIV-1 serostatus 1.56 (0.64–3.80) 1.12 (0.41–3.08)
Alcohol intake 1.46 (0.63–3.41) 1.92 (0.72–5.16)
Type 2 diabetes mellitus 1.99 (0.26–14.17) 1.67 (0.12–14.28)
a Abbreviations: INH, isoniazid; AUC0–24, area under the concentration-time curve from 0 to 24 h.
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significantly increased proportion of side effects in patients with
isoniazid AUC0–24 values in the highest quartile. Overall inci-
dences of drug side effects secondary to isoniazid reported in the
literature range from 1 to 3% for dermatological, gastrointestinal,
and neurological side effects and from 1 to 17% for hypersensitiv-
ity reactions (20). Thirteen of the 16 patients who had side effects
and were in the highest isoniazid AUC0–24 quartile were coin-
fected with HIV-1. Studies have shown that 8 to 20% of patients
taking isoniazid can develop antinuclear antibodies. This is in-
creased in slow acetylators (44) and may be potentiated in HIV-1
coinfection. One randomized controlled clinical trial conducted
in Japan showed that isoniazid-related liver injury in the first 8
weeks of anti-TB treatment occurred in 78% of slow acetylators
given standard 5-mg/kg doses, compared to 0%of slow acetylators
given 2.5-mg/kg doses (45). Hence, significant pharmacokinetic
variability for isoniazid, even with standard dosing, may contrib-
ute to toxicity.
Therewere several limitations in this study. Pharmacogenomic
data, such as NAT2 and SLCO1B1 genotypes, were not available
for incorporation into the population PK models. Drug concen-
tration sampling was not repeated at different times during treat-
ment and hence may have under- or overestimated the IOV
secondary to changes in weight and immune reconstitution sec-
ondary toART.Aprevious study ofHIV-1-coinfected patients did
not find an independent effect on TB pharmacokinetics for first-
dose ART or steady-state ART (at 2 weeks) compared to day 1 of
anti-TB drugs (6). There was no routine monitoring of blood
tests, such as liver and renal function tests. Hence, asymptomatic
adverse drug reactions would not have been ascertained.
In this outpatient setting with a high burden of HIV-1-coin-
fected patients, the majority of whom were undergoing immune
reconstitution onART, there was no evidence thatHIV-1 coinfec-
tion led to lower anti-TB drug concentrations.
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